Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
AstraZeneca
Dow
Johnson and Johnson
Medtronic

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR EPINEPHRINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Epinephrine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000290 ↗ Stress Hormones and Human Cocaine Use - 7 Completed University of Minnesota Phase 1 1997-05-01 The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration.
NCT00000290 ↗ Stress Hormones and Human Cocaine Use - 7 Completed University of Minnesota - Clinical and Translational Science Institute Phase 1 1997-05-01 The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration.
NCT00000290 ↗ Stress Hormones and Human Cocaine Use - 7 Completed National Institute on Drug Abuse (NIDA) Phase 1 1997-05-01 The purpose of this study is to determine the HPA axis and adrenergic system activation in response to cocaine administration.
NCT00001724 ↗ Local Flurbiprofen to Treat Pain Following Wisdom Tooth Extraction Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 1997-11-01 This study will evaluate the effectiveness of the non-steroidal anti-inflammatory drug flurbiprofen (Ansaid® (Registered Trademark)) in relieving pain following oral surgery. Flurbiprofen is approved by the Food and Drug Administration for treatment of arthritis pain. Patients 16 years of age and older requiring third molar (wisdom tooth) extraction may be eligible for this study. Patients will undergo oral surgery to remove two lower third molar teeth. Before surgery, they will be given a local anesthetic (lidocaine with epinephrine) injected in the mouth and a sedative (Versed) infused through a catheter (thin plastic tube) placed in an arm vein. At the time of surgery, patients will also be given flurbiprofen or a placebo formulation (look-alike substance with no active ingredient) directly into the extraction site and a capsule that also may contain flurbiprofen or placebo. One in seven patients will receive only placebo. All patients will fill out pain questionnaires and stay in the clinic for up to 6 hours for observation of bleeding and medication side effects. Patients who do not have satisfactory pain relief from the test medicine after surgery may request a standard pain reliever. A small blood sample will be collected during surgery and at 15 minutes, one-half hour and 1, 2, 3, 4, 5, 6, 24 and 48 hours after surgery to measure flurbiprofen blood levels. A total of 33 ml (about 2 tablespoons) of blood will be drawn for these tests. Samples collected on the day of surgery will be drawn from the catheter used to administer the sedative; the 24- and 48-hour samples will be taken by needle from an arm or hand vein. Urine samples will also be collected between 4 and 6 hours after surgery and again at 24 and 48 hours after surgery.
NCT00002659 ↗ Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status Matrix Pharmaceutical Phase 3 1995-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer.
NCT00003044 ↗ Chemotherapy in Treating Patients With Liver Cancer Unknown status Matrix Pharmaceutical Phase 2 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and epinephrine administered directly into the tumor in treating patients who have primary liver cancer that cannot be removed during surgery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Epinephrine

Condition Name

Condition Name for Epinephrine
Intervention Trials
Pain 40
Postoperative Pain 30
Pain, Postoperative 29
Anesthesia, Local 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Epinephrine
Intervention Trials
Pain, Postoperative 77
Pulpitis 31
Osteoarthritis 22
Bronchiolitis 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Epinephrine

Trials by Country

Trials by Country for Epinephrine
Location Trials
United States 380
Canada 51
Egypt 30
Korea, Republic of 25
Brazil 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Epinephrine
Location Trials
California 48
North Carolina 27
New York 25
Texas 24
Maryland 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Epinephrine

Clinical Trial Phase

Clinical Trial Phase for Epinephrine
Clinical Trial Phase Trials
Phase 4 218
Phase 3 60
Phase 2/Phase 3 28
[disabled in preview] 129
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Epinephrine
Clinical Trial Phase Trials
Completed 349
Unknown status 74
Recruiting 67
[disabled in preview] 125
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Epinephrine

Sponsor Name

Sponsor Name for Epinephrine
Sponsor Trials
University of California, San Diego 13
University of Minnesota 10
Cairo University 9
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Epinephrine
Sponsor Trials
Other 839
Industry 78
NIH 26
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
McKesson
Express Scripts
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.